Breastfeeding is vital for infant health and recommended by WHO as the sole source of nutrition for the first 6 months of life. Yet, millions of mothers face mastitis - a painful breast inflammation affecting 1 in 4 breastfeeding women worldwide. Up to 38% are forced to stop breastfeeding early, despite its critical role in infant nutrition.
Today, standard of care relies mainly on antibiotics, potentially exposing over 30 million infants annually to antibiotic transfer through breast milk.
Early weaning and antibiotic exposure can disrupt infant microbiomes, raising risks of allergies, immune disorders, and long-term health complications.
Mastitia is changing this. We are developing an effective, microbiome-friendly solution for mastitis care - helping mothers continue breastfeeding while reducing dependence on antibiotics.
Our innovation supports WHO’s sustainable development goals by improving maternal and infant health while combating antimicrobial resistance.
Together, let’s safeguard breastfeeding and improve global health for mothers and infants.
Behind Mastitia stand two experienced founders with a shared vision: to transform global mastitis care. To bring this vision to life, we collaborate with Professor Sarah Lebeer and Ilke De Boeck from the University of Antwerp, internationally recognized for their pioneering work in microbiome and women’s health research, and benefit from the guidance of advisor Henrik Knudsen, whose expertise strengthens our strategic direction and growth.
Emilie Glad Bak, PhD
CSO. Trained in systems biology and microbiomes from leading academic and biotech institutions. Emilie works at the intersection of women’s health and infectious diseases (AMR), building on a strong scientific foundation to develop globally impactful solutions.
Daniel Hovel Hansen, MSc
CEO. Seasoned expert in commercialization of human health biosolutions, with a specific focus on Infant and Women’s Health. Daniel brings extensive experience in commercial development and leadership across global markets and health categories.
With support from Innovation Fund Denmark, Mastitia is building the future of microbiome-friendly mastitis care.
We are open to additional funding from private and public partners. Investors are welcome to contact us at hello@mastitia.com to explore opportunities together.
Mastitia ApS
Pilekæret 27
2840 Holte
Denmark
CVR: 45754294
